Ultrasound contrast agent Optison from Molecular Biosystems has been approved in Europe, according to San Diego-based MBI and its marketing partner, Mallinckrodt of St. Louis. Mallinckrodt now has rights to sell the agent in the 15 countries of the
Ultrasound contrast agent Optison from Molecular Biosystems has been approved in Europe, according to San Diego-based MBI and its marketing partner, Mallinckrodt of St. Louis. Mallinckrodt now has rights to sell the agent in the 15 countries of the European Union, with sales to begin first in Germany, Austria, and the U.K.
MBI this month also announced financial results for the fourth quarter (end-March) that showed the impact of Optison sales in the U.S., which began in January (SCAN 1/14/98). MBIs Optison sales to Mallinckrodt totaled $700,000, exceeding the companys expectations. MBIs total revenues for the period were $2 million, compared with sales of $1.5 million in the fourth quarter of 1996. MBI had a net loss of $5.9 million in the most recent period, compared with a net loss of $4.3 million in the fourth quarter of 1996.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.